Early risk screening for Alzheimer's disease
Key words:
Qankorey
Classification:
Products
Colloidal gold immunochromatography technology was used to qualitatively detect the Aβ concentration level in human urine, and the world's first AD urine test early screening reagent.
Product Features
- Early screening:Screening of people at high risk of AD
- Non-invasive:Non-invasive sampling urine test
- Hypersensitivity:Detection sensitivity up to picogram level
- Fast:Results can be reported 10 minutes after the sample is dropped
- Convenient:Add 100uL urine, easy to detect
- Accurate:The positive judgment value was 0.5ng/mL, and the detection rate was 95%
Product Application
- It can be applied to the regular physical examination population over 45 years old;
- Family history of dementia;
- Memory impairment and suspected cognitive impairment;
- Cardiovascular and cerebrovascular diseases and cerebrovascular injuries (stroke, cerebral hemorrhage, cerebral infarction, etc.);
- Chronic diseases (hypertension, diabetes, hyperlipidemia, etc.), snoring and homocysteine deficiency;
- Anxiety, depression, bad habits (smoking and drinking, lack of exercise in the middle of obesity, long-term lack of sleep, etc.).
Recommend Products
A biotechnology company focusing on key technologies for Alzheimer's disease (AD), a global medical challenge.
Domestic business consulting:86-0731-85714218
Company E-mail:yingxiao@qankorey.com
International Business Consulting:86-18874232226
Company E-mail:lisa@qankorey.com
Company address: 12F, Building 15, 188 Middle Huanbao Road, Yuhua District, Changsha, Hunan , 410116, China
Production Address: 4th Floor, Building 7, Yuhua Intelligent Manufacturing Center, No.2 Hongda Road, Tongsheng Street, Yuhua District, Changsha, Hunan , 410000, China
Public Number
Small program
Jingdong
Taobao